Executive Summary
ARGX-109 is an IL-6 targeting antibody in proof-of-concept stage, part of argenx's broader immunology pipeline.
ARGX-109
IL-6 · Antibody (anti-IL-6)
Mechanism of Action[Corp '26 S23]
Target Biology[Corp '26 S23]
IL-6 is a pro-inflammatory cytokine involved in many autoimmune and inflammatory diseases. Blocking IL-6 can reduce inflammation and disease activity.
Clinical Data
No clinical trial data available.
Market Opportunity
Catalysts & Upcoming Events
No catalyst data available.